NFL lineman, Ike Boetgger, joins Dave as his first "in-studio" guest to discuss the power of individualized medicine en route achieving his healthiest version of himself.

This week, Dave knapp interviews Fractyl, CEO, Harith Rajagopalan and discusses a new treatment that may allow patients to maintain their weight loss post GLP-1.

Christopher Lafron AKA Airsoft Fatty talks about his weight loss and shares his takes on obesity. (Language warning) Dr. Leslie Golden shares her obesity journey from her perspective as a physician and talks obesity medicine advocacy. Ali from Fit Flavor Fun shares tips for newbies on GLP-1 meds!

Pfizer buys Metsera, and Dave covers the compound Tirzepatide threat landscape

Last week, Dr. Robin Pashby’s viral presentation “What We Carry” lit up the obesity and GLP-1 community. If you missed it, go watch that talk first — it’s one of the most powerful pieces on living with obesity you’ll ever see. This is my in-depth interview with Dr. Pashby, where we dig deeper into the stories behind “What We Carry.” She opens up about the scale’s power, the rules we live by, the “fire escape” moments we all carry, and what it truly means to separate weight from worth. If her viral talk hit you in the heart, this conversation will help you process it, personalize it, and maybe even begin to let go of some of that hidden weight.

Dave covers the week's news in GLP-1

🚨 FDA cracks down on compounded GLP-1 medications, raising questions about the future safety, quality, supply, and cost. In this episode of On The Pen Live, we break down what the FDA’s new “green list” means for patients relying on compounded semaglutide and tirzepatide, including risks like dosing errors, unapproved salt forms, and hospitalizations. We also cover two massive research moves shaking up the future of obesity and diabetes care: ✅ Novo Nordisk + Novonesis team up on gut microbiome therapies, using probiotics and prebiotics (synbiotics) to prevent obesity and improve blood sugar and cholesterol. ✅ Eli Lilly + Remedium Bio launch a gene therapy partnership that could replace weekly GLP-1 injections with a single, long-acting shot. PLUS: An exclusive interview with Alicia, cofounder of Claimable, about the class action lawsuit against CVS Caremark for forcing patients to switch from Zepbound to Wegovy. We talk timelines, how to get involved, and what it means for patient choice in obesity treatment.

This episode of On The Pen: The Weekly Dose Podcast breaks down four major stories in obesity medicine: the FDA’s approval of Teva’s so-called “generic” Saxenda at a sky-high price, Wegovy’s accelerated approval in MASH, Novo Nordisk’s headline-grabbing but shaky 57% cardiovascular benefit claim, and Eli Lilly’s decision to scrap its oral GLP-1 naperiglipron. We cut through the spin to ask what these developments really mean for patients fighting for access and better treatment options.

Sabina from GLPwinner.com who was in attendance yesterday, sits down in an exclusive OTP interview to discuss yesterday’s s hearing between Eli Lilly and Mochi health.

In Today's live Podcast, Dave covers the latest breaking news in Obesity Medicine, including fresh data on an oral #GLP1 that we have been following for years from #VikingTherapeutics Learn more about he #VikingTide pill!

GLP-1 microdosing is one of the hottest and most controversial topics in obesity medicine right now. Can lowering your dose instead of quitting completely help you keep the weight off? In this exclusive interview, Noom CEO Geoff Cook responds to questions about microdosing, GLP-1 off-ramping, and how Noom supports patients using medications like Mounjaro, Zepbound, Wegovy, and Ozempic.

Zepbound now leads two-thirds of the U.S. obesity market—and that’s just the beginning. In this video, we break down the biggest headlines from Eli Lilly’s latest earnings call, including: ✅ Over 1 million Zepbound vials prescribed in Q2 ✅ New Phase 3 tirzepatide trial for type 1 diabetes ✅ 39% reduction in all-cause mortality (MACE-3) ✅ Orforglipron data and pricing strategy revealed ✅ Retatrutide and the future of complex obesity care ✅ Employer coverage shifts and LillyDirect updates ✅ The real reason behind Lilly’s compounding crackdown ✅ How Canadian generics might replace U.S. compounders 🎯 Whether you’re on GLP-1 meds or just trying to get answers in a system that keeps moving the goalposts, this episode is for you.

Novo Nordisk Q2 2025 Earnings: What It Means for GLP-1s, Compounded Semaglutide, Amycretin & Obesity Treatment In this breakdown of Novo Nordisk’s Q2 2025 earnings call, I cover the biggest takeaways for anyone using or considering GLP-1 medications like Ozempic, Wegovy, Rybelsus, and semaglutide for obesity, type 2 diabetes, and related comorbidities.

This week Dave covers all the obesity medicine news that will empower you to have more informed conversations with your doctor. This week's topics include: FDA Statement on Non Branded GLP-1 Meds Lilly is Getting to Root Cause Obesity Medicine, Beyond Tirzepatide A Landmark Study for Mounjaro Preview of Upcoming Earnings Calls

Breaking News Today from the Trump administration on the cost of GLP-1

In this week's epidsode of The Weekly Dose Podcast, Dave covers some whacky versions of Retatrutide that are popping up from interesting sources. He also covers all the big stories in GLP-1 from this past week.

This week Dave covers: The Obesity Society congressional hearing slamming compounded #tirzepatide and #semaglutide A study that may show GLP-1 reduces breast cancer tumors: A study that may show GLP-1 increases size of rare neuroenocrine tumors:

In this episode of On The Pen: Faces of the Fight, I sit down with Connecticut State Senator Matt Lesser, the lawmaker behind one of the boldest health policy moves in recent memory. We talk about Connecticut’s newly passed bipartisan prescription drug affordability bill and the groundbreaking provision buried inside it — a plan to petition the federal government for permission to manufacture their own GLP-1 medications like Ozempic. Senator Lesser explains how this little-known federal law could allow Connecticut to override pharmaceutical patents in the public interest, why the state is spending over 150 million dollars a year on GLP-1s, and how this approach could bring drug prices down not just in Connecticut, but potentially nationwide. We also dig into timelines, political strategy, and the real-world implications of a state trying to break Big Pharma’s pricing model. If you care about access, affordability, and the future of obesity treatment in America, this is one you don’t want to miss.

Get All The Referenced Links: https://linktr.ee/manonthemounjaro